Zevalin-beam for Aggressive Lymphoma

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

ibritumomab tiuxetan

0.4 mCi/kg

PROCEDURE

BEAM chemotherapy and autologous stem-cell transplantation

Trial Locations (9)

55905

Mayo Clinic, Rochester

Unknown

Mayo Clinic Arizona, Scottsdale

Cedars Sinai Medical Center, Los Angeles

Moffitt Cancer Center, Tampa

Northwestern University, Chicago

Georg-August Universität, Göttingen

Chaim Sheba Medical Center, Tel Litwinsky

VU Medical Center, Amsterdam

91010-3000

City of Hope National Medical Center, Duarte

All Listed Sponsors
collaborator

City of Hope Medical Center

OTHER

collaborator

Amsterdam UMC, location VUmc

OTHER

collaborator

University of Göttingen

OTHER

lead

Sheba Medical Center

OTHER_GOV

NCT00491491 - Zevalin-beam for Aggressive Lymphoma | Biotech Hunter | Biotech Hunter